|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM322152380 |
| 003 |
DE-627 |
| 005 |
20250301032044.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||jpn c |
| 024 |
7 |
|
|a 10.14989/ActaUrolJap_67_2_57
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1073.xml
|
| 035 |
|
|
|a (DE-627)NLM322152380
|
| 035 |
|
|
|a (NLM)33657772
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Morooka, Daichi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Tumor Shrinkage as a Prognostic Factor of Metastatic Renal Cell Carcinoma in the Era of Molecular Targeted Therapy
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.03.2021
|
| 500 |
|
|
|a Date Revised 05.03.2021
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We evaluated the impact of tumor shrinkage (TS) induced by molecular targeted therapy as the first-line systemic therapy on the survival of patients with metastatic renal cell carcinoma (mRCC). A total of 67 patients with mRCC who received first-line molecular targeted therapy were included in this study. Sixty patients were evaluable by response evaluation criteria in solid tumors. Patients underwent the first evaluation at 8-12 weeks after the start of the therapy. Twenty patients had TS ≧30%, 32 from 30% to -20%, and 8 ≦-20%. The median overall survival periods of patients who achieved TS ≧30%, from 30% to -20%, and ≦-20% at first evaluation were 41.0, 35.0, and 11.5 months, respectively. Univariate and multivariate analyses showed that TS of≧0%, in addition to negative C-reactive protein and the absence of bone metastasis were good predictors of overall survival. The patients who achieved 0% or more at the initial evaluation had longer survival than those who had no tumor reduction (40.0 months vs 12.0 months, p<0. 001). These findings suggest that early TS affects overall survival in real practice. We should consider alternative therapies for patients who have not achieved tumor reduction at the initial evaluation
|
| 650 |
|
4 |
|a Journal Article
|
| 700 |
1 |
|
|a Takahashi, Atsushi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kurisu, Tomoyo
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okabe, Ko
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kyoda, Yuki
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takagi, Yoshio
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 67(2021), 2 vom: 01. Feb., Seite 57-61
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnas
|
| 773 |
1 |
8 |
|g volume:67
|g year:2021
|g number:2
|g day:01
|g month:02
|g pages:57-61
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.14989/ActaUrolJap_67_2_57
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 67
|j 2021
|e 2
|b 01
|c 02
|h 57-61
|